KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Cash (2016 - 2025)

Historic Change in Cash for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $36.3 million.

  • Biomarin Pharmaceutical's Change in Cash rose 11223.18% to $36.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $574.7 million, marking a year-over-year increase of 62257.97%. This contributed to the annual value of $187.7 million for FY2024, which is 51352.79% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Change in Cash of $36.3 million as of Q3 2025, which was up 11223.18% from $165.0 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Change in Cash ranged from a high of $267.4 million in Q4 2024 and a low of -$296.7 million during Q3 2024
  • Its 5-year average for Change in Cash is $31.6 million, with a median of $18.2 million in 2021.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Change in Cash tumbled by 89529.29% in 2023 and then surged by 140317.3% in 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Change in Cash (Quarter) stood at -$29.9 million in 2021, then dropped by 23.83% to -$37.0 million in 2022, then increased by 18.11% to -$30.3 million in 2023, then surged by 982.87% to $267.4 million in 2024, then tumbled by 86.43% to $36.3 million in 2025.
  • Its last three reported values are $36.3 million in Q3 2025, $165.0 million for Q2 2025, and $106.0 million during Q1 2025.